899350-32-4

Basic information

• Product Name: Benzenebutanoic acid, 3-bromo-
• Synonyms: 3-bromoBenzenebutanoic acid;Benzenebutanoic acid, 3-bromo-
• CAS NO: 899350-32-4
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.11
• Mol File: 899350-32-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, Methanol (Slightly)
• CAS DataBase Reference: Benzenebutanoic acid, 3-bromo-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanoic acid, 3-bromo-(899350-32-4)
• EPA Substance Registry System: Benzenebutanoic acid, 3-bromo-(899350-32-4)

Safety Data

• Hazardous Substances Data: 899350-32-4(Hazardous Substances Data)

Usage

Uses

3-Bromo-benzenebutanoic Acid is a reactant used in the preparation of pyrrolo-(di)-benzazocinones via an intramolecular cyclization of N-acyliminium ions formed from 4,4-diethyoxybutyl amides (Erratum)

Upstream product

• 62903-13-3 4-(3-bromophenyl)-4-oxo-butyric acid 
• 3132-99-8 m-bromobenzoic aldehyde 
• 884504-63-6 4-(3-bromophenyl)-4-oxobutanenitrile 
• 28229-69-8 2-(3-bromophenyl)ethan-1-ol 
• 57186-65-9 1-bromo-3-(2'-iodoethyl)benzene 
• 108-86-1 bromobenzene 
• 40422-70-6 1-bromo-3-(2-bromoethyl)benzene 

Downstream Products

• 1616372-55-4 N-((3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-3-yl)methyl)benzenesulfonamide 
• 1616372-95-2 3-(3-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1616372-56-5 3-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-methoxy-[1,1'-biphenyl]-3-yl)propanoic acid 
• 1596464-90-2 4-(3-bromophenyl)butanehydrazide 
• 1616372-60-1 3-(3-(3'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-3-yl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1616372-70-3 2-(4-(3-bromophenyl)butanoyl)-N-ethylhydrazinecarboxamide 
• 1616372-66-7 2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1'-biphenyl]-4-yl)acetic acid 
• 1616373-16-0 methyl 2-(3-(benzyloxy)-3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-4-yl)acetate 
• 1616372-69-0 3-(3-(3-bromophenyl)propyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1616373-17-1 methyl 2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-3-hydroxy-[1,1'-biphenyl]-4-yl)acetate 
• 1616372-71-4 3-(3-(3-bromophenyl)propyl)-1-(4-(tert-butyl)benzyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one 
• 1616372-72-5 1-(4-(tert-butyl)benzyl)-4-ethyl-3-(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1H-1,2,4-triazol-5(4H)-one 
• 1616372-83-8 C₃₄H₄₁N₃O₃ 
• 1616372-36-1 2-(3'-(3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-[1,1'-biphenyl]-3-yl)acetic acid 

Relevant articles and documents

NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE

PROBLEM TO BE SOLVED: To provide a compound that specifically activates an LPA4 receptor, and a pharmaceutical composition containing the same. SOLUTION: This invention relates to a novel lysophosphatidic acid derivative that has an agonistic action on an LPA4 receptor and is useful for the prevention and/or treatment of a disease with angiodysplasia caused by the LPA4 receptor, or a disease associated with angiopathy, or symptoms associated therewith. This invention also relates to a pharmaceutical composition containing the lysophosphatidic acid derivative. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D 3 analogues with aromatic side chains attached at C-17

Two new analogues of the steroid hormone 1α,25-dihydroxyvitamin D3 with aromatic side chains attached at C-17 were designed to investigate their effects on VDR, HL-60 cell differentiation and tumor cell proliferation. These analogues were prepared by the classical photochemical ring opening approach. After the protection of both the 1α- and 3β-hydroxyl in 1α-hydroxydehydroepiandrosterone with TBS groups, followed by bromination with NBS and debromination in the presence of γ-collidine, the diene intermediate was obtained. Hydrazone formation followed by iodine oxidation gave a vinyl iodide. The aromatic side chain at C-17 was introduced via the Negishi coupling of the resulting intermediate with an in situ generated zinc reagent with the substituted aryl bromide (CD-side chain) in the presence of catalytic amount of Pd(PPh3)4. After the removal of the TBDMS and MOM protective groups, followed by UV irradiation and the subsequent thermal reaction, the 1α,25-(OH) 2-D3 analogues with a substituted phenyl ring attached at C-17 to replace the C-20 and C-21 were prepared. In the VDR competitive binding assay, compounds 2 and 3 almost lost their binding ability, and were only 0.01% and 0.015% as potent as the 1α,25-dihydroxyvitamin D3. However, compounds 2 and 3 were as potent as 1α,25-(OH)2-D3 in inducing HL-60 cell differentiation at concentrations of 30, 100, 300, 1000 nM, respectively. Moreover, compounds 2 and 3 exhibited similar or better antiproliferative potency against MCF-7 human breast cancer cells, the IC 50 values for analogues 2, 3 and the natural hormone were 7.08, 7.56, and 12.5 μM, respectively.

A facile synthesis of pyrrolo-(di)-benzazocinones via an intramolecular N-acyliminium ion cyclisation

A facile, moderate to high yielding synthesis of hexahydro-(di)- benzazocinones is described via an intramolecular N-acyliminium ion cyclisation. The iminium ion intermediates are formed from the readily available 4,4-diethoxybutyl amides with an excess of triflic acid. For electron-withdrawing substituents, better yields were obtained from the pre-formed 2-hydroxypyrrolidine amides. From NMR studies, at ambient temperatures the pyrrolo-benzazocin-3-ones exist as a slowly equilibrating mixture of two conformations.